What Getinge Doubters Got Wrong

If you had looked at Getinge on 1 January 2026, you would have seen a business pulled between two very different stories on tariffs, regulation, and digital health upside. For Getinge shareholders, the return from the start of the year was 33.0%, including dividends. If you were weighing a buy decision then, how would you have balanced the margin risks against the push into advanced infection control and software backed care?

A Narrative on Simply Wall St is one investor's written case for a company, with its growth, margin and multiple assumptions spelled out. Those assumptions imply an estimated Fair Value.

Getinge is not the only name tied to this theme. Zero in on 126 healthcare AI stocks and compare how each one is priced.

The Two Stories Investors Were Debating On Getinge

The shares cost SEK218 at the start of the period, and Getinge sat between two sharply different stories about where value might sit.

The bullish Narrative put Fair Value at SEK236, or 8% above the start price. It leaned on assumptions of 5.1% revenue growth and an 8.4% profit margin supported by digital health tools and infection control offerings.

The bearish Narrative pointed to Fair Value of SEK165, or 24% below the start price. It highlighted rising tariffs and tighter regulation as key threats to profitability and supply chain stability.

What The Evidence Did To The Getinge Argument

Getinge’s Q3 2026 report showed revenue of SEK8,446m and net income of SEK719m, with net margin at 8.5% compared with 6.9% a year earlier. That margin outcome sat above both Narratives’ 8.4% assumption and supported the more optimistic view that advanced therapies and infection control could sustain profitability despite tariff pressure.

The useful takeaway is clear. When a thesis hangs on margin resilience, focus on reported profitability percentages against the original claim, not just whether sales or earnings moved in the right direction.

What Getinge's Year To Date Run Now Prices In

Getinge now trades at SEK282 from the start of the year, with a return of 33.0%. The selected Narrative’s Fair Value sits below the current price, which frames today’s level as demanding a lot from the execution story.

You would need to judge whether Getinge can keep translating higher recurring and high margin revenue into stronger EBITA margins despite regulatory, tariff and litigation headwinds.

"The main thing that has to go right is that Getinge converts its higher share of recurring and high margin revenue and the planned unwind of extraordinary quality costs into sustainably stronger EBITA margins, without this being offset by weaker regions or product lines."

One Narrative disagrees with today's price. → See where this Narrative says Getinge should trade

How Could You Get There Earlier?

By the time a rally makes headlines, you are reading about returns someone else has already earned. Why not go straight to the source and look for your own contrarian opportunity? These three companies trade below our estimated value.

• Company 1 - 36% below our estimate - sells power and refrigeration systems for data center and industrial projects.
• Company 2 - 26% below our estimate - expands manufacturing capacity to fulfill defense electronics, missile and space contracts.
• Company 3 - 32% below our estimate - tightens credit standards while increasing secured lending to large infrastructure borrowers.

Those are three of them. See all 213 potentially undervalued companies →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com